Caerulomycin A – 5 mg

Brand:
Cayman
CAS:
21802-37-9
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

Caerulomycin A is an fungal metabolite originally isolated from Actinoalloteichus with antifungal and immunosuppressant activites.{47448,47449,47450,47451} It inhibits the growth of C. albicans, C. glabrata, and C. krusei (MICs = 0.78-1.56, 0.39-0.78, and 0.78-1.56 μg/ml, respectively).{47448} Caerulomycin A induces expansion of CD4+Foxp3+ regulatory T cells (Tregs) and decreases the number of Th1 and T17 cells in vitro via increased TGF-β-mediated Smad3 activity and reduces IFN-γ-induced STAT1 signaling.{47449} In vivo, caerulomycin A (10 mg/kg) reduces IL-6, TNF-α, and IFN-γ production, inflammation, and synovitis in a mouse model of collagen-induced arthritis. Caerulomycin A suppresses the differentiation of Th2 cells and reduces levels of IL-4, IL-5, IL-13, and IgE and eosinophil lung infiltration in a mouse model of ovalbumin-induced asthma.{47450} It also increases production of Tregs, reduces production of Th1, Th17, and CD8 T cells, and reduces disease severity in a mouse model of experimental autoimmune encephalomyelitis (EAE).{47451}  

 

Available on backorder

SKU: 27625 - 5 mg Category:

Description

A fungal metabolite with antifungal and immunosuppressant activities; inhibits the growth of C. albicans, C. glabrata, and C. krusei (MICs = 0.78-1.56, 0.39-0.78, and 0.78-1.56 μg/ml, respectively); induces expansion of Tregs and decreases the number of Th1 and T17 cells in vitro; reduces IL-6, TNF-α, and IFN-γ production, inflammation, and synovitis in a mouse model of collagen-induced arthritis at 10 mg/kg; suppresses the differentiation of Th2 cells and reduces levels of IL-4, IL-5, IL-13, and IgE and eosinophil lung infiltration in a mouse model of ovalbumin-induced asthma; increases production of Tregs, reduces production of Th1, Th17, and CD8 T cells, and reduces disease severity in a mouse model of EAE


Formal name: (E)-4-methoxy-[2,2′-bipyridine]-6-carboxaldehyde oxime

Synonyms: 

Molecular weight: 229.2

CAS: 21802-37-9

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Antifungals||Product Type|Biochemicals|Natural Products|Microbial Metabolites||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Allergy||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Immunology & Inflammation|Immunosuppressants||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Immunology & Inflammation|Pulmonary Diseases||Research Area|Infectious Disease|Fungal Diseases|Candidiasis